Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 18;9:19330. doi: 10.1038/s41598-019-55885-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

OligoGM1 effect on fine motor movement (sensorimotor) measured by irritant removal test. (A–E) B4galnt1^+/− mice at 270 days of age were IP injected with 20 mg/kg OligoGM1 (n = 12) or with BSS (n = 12) daily for 4 weeks. WT mice (n = 9) of the same age were IP injected with BSS daily for 4 weeks. Data are expressed as mean ± SEM [one-way ANOVA followed by Bonferroni’s multiple comparisons test]. (A) Week 0, F_(2,21) = 3.710, *p < 0.05 B4galnt1^+/− + BSS and B4galnt1^+/− + OligoGM1 compared with WT. (B) Week 1, no significant difference between B4galnt1^+/− + BSS or + OligoGM1 compared with WT. (C) Week 2, F_(2,19) = 5.256, *p < 0.05 B4galnt1^+/− + BSS compared with WT and B4galnt1^+/− + OligoGM1. (D) Week 3, F_(2,30) = 6.783, *p < 0.05 B4galnt1^+/− + BSS compared with WT and **p < 0.01 B4galnt1^+/− + BSS compared with B4galnt1^+/− + OligoGM1. (E) Week 4, F_(2,19) = 6.027, **p < 0.01 B4galnt1^+/− + BSS compared with WT and B4galnt1^+/− + OligoGM1; (F) overview of the 4 weeks’ treatment (●WT + BSS; ■ B4galnt1^+/− + BSS; ▼ B4galnt1^+/− + OligoGM1).